Jushi Q2 revenue beats analyst estimates, posts record wholesale on higher production volumes
Analyst view
The current average analyst rating on the shares is buy. The breakdown of recommendations is 4 strong buy or buy, 1 hold, and no sell or strong sell ratings.
The median 12-month price target for Jushi Holdings Inc is C$1.70, about 198.2% above its July 27 closing price of C$0.57.
Tax benefit and outlook
Jushi recognized a $6.4 million tax benefit from the federal rescheduling of medical marijuana.
The company said Virginia adult-use cannabis sales are set to begin July 1, 2027. Jushi said it is advancing cultivation and processing investments to support the transition to adult-use sales, with a focus on expanding distribution, optimizing its retail portfolio, and maintaining liquidity in the second half.
Quarterly revenue beats estimates
Jushi said second-quarter revenue rose 10% year over year, beating analyst expectations. Revenue came in at $71.30 million versus the $67.52 million consensus estimate from four analysts.
The company reported a second-quarter net loss of .
